PLEKHG5 is stabilized by HDAC2-related deacetylation and confers sorafenib resistance in hepatocellular carcinoma

Sorafenib is the first FDA-approved first-line targeted drug for advanced HCC. However, resistance to sorafenib is frequently observed in clinical practice, and the molecular mechanism remains largely unknown. Here, we found that PLEKHG5 (pleckstrin homology and RhoGEF domain containing G5), a RhoGE...

Descripción completa

Detalles Bibliográficos
Autores principales: Sha, Yu, Pan, Mingang, Chen, Yunmeng, Qiao, Liangjun, Zhou, Hengyu, Liu, Dina, Zhang, Wenlu, Wang, Kai, Huang, Luyi, Tang, Ni, Qiu, Jianguo, Huang, Ailong, Xia, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227013/
https://www.ncbi.nlm.nih.gov/pubmed/37248230
http://dx.doi.org/10.1038/s41420-023-01469-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227013/
https://www.ncbi.nlm.nih.gov/pubmed/37248230
http://dx.doi.org/10.1038/s41420-023-01469-z

Ejemplares similares